- A COMPOSITION FOR TREATING OCULAR HYPEREMIA AND A METHOD FOR TREATING OCULAR HYPEREMIA WITH THE SAME
-
A composition for use in the treatment of ocular hyperemia includes an anti-angiogenic agent and an ? adrenergic receptor agonist. A method for treating ocular hyperemia for a patient includes inhibiting a plurality of kinase receptors of the patient with an MKI; and activating alpha adrenergic receptor of the patient with an agonist of the receptor.
- -
-
Paragraph 0050; 0052
(2019/12/16)
-
- COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS AND SKIN DISEASES
-
Disclosed is a compound of formula I or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof, which is useful for treatment of eye disorders, skin diseases and/or complications associa
- -
-
Paragraph 00133; 00137
(2019/06/05)
-
- A TOPICAL COMPOSITION FOR TREATING ROSACEA AND A METHOD FOR TREATING ROSACEA WITH THE SAME
-
A composition for use in the treatment of rosacea includes a multi-kinase inhibitor that inhibits both a Vascular Endothelial Growth Factor Receptor and a Fibroblast Growth Factor Receptor. A method for treating rosacea for a patient includes inhibiting a Vascular Endothelial Growth Factor Receptor of the patient; and inhibiting a Fibroblast Growth Factor Receptor of the patient.
- -
-
Paragraph 0062; 0064
(2018/12/14)
-
- DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS
-
The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.
- -
-
Page/Page column 271
(2018/10/19)
-
- METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
-
A method of treating or preventing acute erythema in a human in need thereof by topical administration of an effective amount of an alpha adrenergic receptor agonist or pharmaceutically acceptable salt thereof is claimed. The preferred alpha adrenergic re
- -
-
Page/Page column 14
(2011/05/11)
-
- PRE-SURGICAL TREATMENT
-
The invention relates to a method of reducing post-surgical bleeding and/or bruising in a patient scheduled to be subjected to a surgical procedure and a patient that was subjected to a surgical procedure. The method involves topically applying to the area and the surrounding area of skin of the patient where the surgical procedure will be or was performed, a pharmaceutical composition comprising an effective amount of brimonidine or a pharmaceutically acceptable salt thereof, prior to performing the surgical procedure and/or following the surgical procedure.
- -
-
Page/Page column 13
(2009/07/25)
-
- Brimonidine Compositions for Treating Erythema
-
The present invention is directed to a pharmaceutical composition including brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable carrier such as a gel or cream. The invention
- -
-
-
- Compounds, formulations, and methods for treating or preventing rosacea
-
In methods, compounds, and topical formulations for treatment of rosacea incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat rosacea and its symptoms.
- -
-
Page/Page column 8
(2008/06/13)
-
- Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
-
A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R1and R2each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R3, R4and R5each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.
- -
-
-
- METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES
-
A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: STR1 and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R 1 and R 2 each is independently selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7-or 8-positions of the quinoxaline nucleus, and R 3, R 4 and R 5 each is located in one of the remaining 5-, 6-, 7-or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide treatment for ischemia.
- -
-
-
- Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
-
Certain (2-imidazolin-2-ylamino) quinoxalines are disclosed. Such quinoxalines reduce or maintain intraocular pressure when administered directly to the eye of a mammal.
- -
-
-
- (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
-
Novel (2-imidazolin-2-ylamino) substituted quinoxalines and -quinazolines, their preparation and use as antihypertensive agents are described.
- -
-
-
